Most treatment modalities are selected according to the molecular subtypes of breast cancers, which incorporate hormone receptors (HR), human epidermal growth factor receptor 2 (HER2), and Ki-67 expression status [3]. This evidence concerns the gene NR4A1 and breast carcinoma.